X-VAX

X-VAX is a clinical-stage biotechnology company dedicated to developing a novel vaccine for the prevention and treatment of herpes simplex virus (HSV) infections. The company's lead candidate, X-Vax-01 (also known as ΔgD-2), utilizes a unique approach by deleting the glycoprotein D (gD-2) gene from the virus, which triggers a potent immune response through antibody-dependent cellular cytotoxicity (ADCC). This platform represents a significant departure from previous HSV vaccine attempts that focused primarily on neutralizing antibodies. X-VAX is currently evaluating its lead candidate in Phase 1 clinical trials for both HSV-1 and HSV-2. Headquartered in Jupiter, Florida, the company is supported by a syndicate of prominent life science investors including Johnson & Johnson Innovation.